HemoShear to Develop Human Cancer Models
Thursday, November 7, 2013
and more effective anticancer drugs may soon be developed thanks to a Small
Business Innovation Research (SBIR) contract recently awarded to HemoShear by
the National Cancer Institute (NCI) of the U.S. National Institutes of Health
(NIH). HemoShear, LLC, located in Charlottesville, is a developer of
advanced human biology systems for applications in drug research and
drugs continue to suffer the highest rate of failure in clinical trials as
compared with other therapeutic areas. HemoShear's contract
with the National Cancer Institute will support the development of human
cell-based systems that replicate the biology of lung and pancreatic tumors,
two of the deadliest groups of tumors.
and pancreatic cancer are terrible diseases that have no effective
treatments," said Dr. Brian Wamhoff, HemoShear co-founder and Vice
President of R&D. "We are using our innovative science to enable
the discovery of new treatments for cancer patients. While billions of
dollars continue to be spent on researching and developing new cancer
therapies, their success rates in clinical trials are not improving. Imagine a
human tumor on the laboratory bench that responds to new therapies as if it
were in the human body. That is what our science is capable of achieving,"
success in this initial stage of tumor system development will lead to
development of other cancer tumor systems, to systems that replicate metastasis
and potentially to new treatments for patient-specific tumors.
is HemoShear's third major area of SBIR funding from separate divisions of the
NIH in three years. We are grateful for the strong support of NIH and the
scientific community. We believe that HemoShear science will yield safer and more
effective therapies while avoiding costly new drug failures," said Jim
Powers, HemoShear's CEO.